In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…
![](https://www.the-rheumatologist.org/wp-content/uploads/2017/02/Generic_shutterstock_DrugsPills_500x270-150x150.jpg)
In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…
A recent study suggests Zilretta, an intra-articular injection for OA knee pain, may lower blood glucose levels in OA patients…
After meeting with the FDA, the makers of intravenous meloxicam plan to resubmit the treatment’s new drug application…
The FDA has expanded the new Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) to include immediate release opioids. The program, which also includes extended release and long acting opioids, will provide education to prescribers and healthcare professionals…
The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…
In late July, the European Commission granted marketing approval for Hyrimoz, which is biosimilar to adalimumab…
Deepan S. Dalal, MD, MPH, Maureen Dubreuil, MD, MS, & David T. Felson, MD, MPH |
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….
The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…
In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…
A recent study compared the efficacy of opioids with nonopioid pain treatments in patients with chronic back pain and hip or knee osteoarthritis. After 12 months, researchers found that treatment with opioids was not superior to treatment with nonopioid medication, with only minor differences in patients’ functional responses to the medications…